8-K 1 organicellrege_8k.htm 8-K










Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934


Date of report (Date of earliest event reported): August 30, 2021



(Exact name of registrant as specified in its charter)


Nevada   000-55008   47-4180540
(State or Other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)


515 North Shore Drive, Miami Beach, Florida   33141
(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: (888) 963-7881




(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each Class   Trading Symbol   Name of each exchange on which registered
None   N/A   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







As used in this Current Report on Form 8-K, and unless otherwise indicated, the terms “the Registrant,” “the Company,” “Organicell,” “we,” “us” and “our” refer to Organicell Regenerative Medicine, Inc. and its subsidiaries.


Item 7.01Regulation FD Disclosure.


On August 30, 2021, an article reporting the results of the treatment of a single COVID-19 Long Hauler patient with the Company’s lead product, Zofin™, was published online in ScienceDirect’s website journal, Respiratory Medicine Case Reports. The article, titled “Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic,” was authored by Dr. Maria Ines Mitrani, our Chief Science Officer, Dr. Allen Meglin, one of our directors, Dr. George Shapiro, our Chief Medical Officer and certain other employees of and consultants to Organicell. ScienceDirect is operated by British-Dutch publisher Elsevier Ltd.


The recently published article can be read in full at:



In addition, a copy of the article is included as Exhibit 99.1 to this report.


In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 7.01, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.   Description
99.1*   Article titled “Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic”



*Furnished but not filed.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By:  /s/ Ian Bothwell
    Ian Bothwell
Chief Financial Officer